Evercore ISI Group Analyst Maintains Zimmer Biomet Holdings Rating, Lowers Price Target

Evercore ISI Group analyst Vijay Kumar has maintained Zimmer Biomet Holdings' rating as "In-Line" while lowering the price target from $102 to $96, a 5.88% decrease. The average one-year target price for ZBH is $107.40, indicating a 16.02% upside from the current price of $92.57. The brokerage recommendation is "Hold" with an estimated GF Value of $143.28, suggesting a 54.78% upside from the current price.

Evercore ISI Group analyst Vijay Kumar has maintained Zimmer Biomet Holdings' rating as "In-Line" while lowering the price target from $102 to $96, a 5.88% decrease. The average one-year target price for ZBH is $107.40, indicating a 16.02% upside from the current price of $92.57. The brokerage recommendation is "Hold" with an estimated GF Value of $143.28, suggesting a 54.78% upside from the current price [1].

In recent months, Zimmer Biomet has seen a series of adjustments to its price targets and ratings from various analysts. For instance, Morgan Stanley lowered its price objective on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company [1]. Similarly, Canaccord Genuity Group cut their price objective from $115.00 to $101.00 and set a "hold" rating for the company [1].

The company's latest earnings report showed strong performance, with earnings per share of $1.81, beating analysts' consensus estimates of $1.77 by $0.04 [1]. Zimmer Biomet reported a net margin of 11.86% and a return on equity of 12.73%. The company's revenue for the quarter was up 1.1% on a year-over-year basis, indicating robust growth.

Institutional investors and hedge funds have also shown interest in Zimmer Biomet, with several increasing their holdings in the company. For example, Dorsey & Whitney Trust CO LLC lifted its holdings by 2.3% in the 4th quarter, and MGO One Seven LLC increased its holdings by 5.1% during the same period [1].

Zimmer Biomet Holdings, Inc., operates as a medical technology company worldwide, designing, manufacturing, and marketing orthopedic reconstructive products, such as knee and hip products, S.E.T. products, craniomaxillofacial, and thoracic products [1].

References:
[1] https://www.marketbeat.com/instant-alerts/zimmer-biomet-nysezbh-given-new-9600-price-target-at-evercore-isi-2025-07-08/